Early Subtypes and Progressions of Progressive Supranuclear Palsy: A Data-Driven Brain Bank Study

Publication date: Jul 04, 2025

Background: Progressive supranuclear palsy (PSP) is typically characterized by vertical supranuclear gaze palsy and early falls, referred to as Richardson’s syndrome (PSP-RS). Other presentations include postural instability (PSP-PI), parkinsonism (PSP-P), speech/language impairment (PSP-SL), frontal presentation (PSP-F), ocular motor dysfunction (PSP-OM), and corticobasal syndrome (PSP-CBS). Differences across the early presentations and in their subsequent progression have yet to be elucidated. Objective: This study aimed to characterize early PSP subtypes and their subsequent progressions using a large postmortem dataset. Methods: An automated pipeline incorporating fine-tuned ChatGPT models was developed. The pipeline collected 195 clinical features with onset information from autopsy-confirmed PSP cases without significant neurodegenerative co-pathologies. Results: A structured clinicopathologic dataset from 588 patients was analyzed. After distilling results with unsupervised clustering, a decision tree model was developed. With five clinical manifestations: frontal presentation, PI, OM, SL, and parkinsonism, this mutually exclusive algorithm identified seven subtypes: PSP-PF (postural and frontal dysfunction), PSP-RS, PSP-PI, PSP-P, PSP-SL, PSP-F, and PSP-OM. PSP-PF, defined by PI and frontal presentation, showed rapid progression, the shortest median disease duration (six years), and high tau burden in cortical and subcortical regions. In PSP-F, frontal presentation preceded other symptoms by four years, and the disease duration was the second longest (nine years) after PSP-P (10 years). PSP-CBS was not identified as an independent subtype. Conclusions: This data-driven study identified a novel, aggressive PSP phenotype characterized by early postural and frontal dysfunction. Early subtyping utilizing the decision tree would help clinicians estimate progression and facilitate early patient recruitment for clinical trials.

PDF

Concepts Keywords
Florida Clinical
Neurodegenerative Early
Tests17 Frontal
Tokyo International
Medrxiv
Onset
Palsy
Preprint
Presentation
Progressive
Psp
Subtypes
Supranuclear
Symptoms
Years

Semantics

Type Source Name
disease MESH Progressive Supranuclear Palsy
disease MESH palsy
disease MESH parkinsonism
disease MESH corticobasal syndrome
disease MESH Alexia
disease MESH tauopathy
disease MESH ophthalmoplegia
disease MESH pseudobulbar palsy
disease MESH dementia
disease MESH neurofibrillary tangles
disease MESH gait
disease MESH Movement Disorder
disease MESH language disorder
disease MESH neurodegenerative disease
disease MESH syndromes
pathway REACTOME Neurodegenerative Diseases
disease MESH Alzheimer’s disease
disease MESH multiple system atrophy
disease MESH frontotemporal lobar degeneration
drug DRUGBANK Thiocolchicoside
disease MESH encephalopathy
disease MESH rest tremor
disease MESH apraxia
disease MESH ataxia
drug DRUGBANK Gold
disease MESH death
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH clinical progression
drug DRUGBANK Levodopa
disease MESH primary progressive aphasia
disease MESH apathy
drug DRUGBANK Modafinil
disease MESH leukoencephalopathy
disease MESH Neurological Disorders
disease MESH Stroke
disease MESH Deafness
disease MESH Communication Disorders
disease MESH Parkinson’s disease
disease MESH COVID 19
disease MESH Privacy
disease MESH Cerebellar ataxia
disease MESH Progressive nonfluent aphasia
disease MESH progressive aphasia
drug DRUGBANK Cannabidiol
disease MESH cerebrovascular disease
disease MESH Lewy body disease
disease MESH myoclonus

Download Document

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *